Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $10,313.31 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 201 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $51.31, for a total transaction of $10,313.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

William Richard White also recently made the following trade(s):

• On Thursday, August 1st, William Richard White sold 201 shares of Disc Medicine stock. The stock was sold at an average price of $43.44, for a total value of $8,731.44.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $49.93 on Friday. Disc Medicine, Inc. has a 1 year low of $25.60 and a 1 year high of $77.60. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -14.77 and a beta of 0.59. The company has a 50-day moving average of $47.67 and a 200 day moving average of $42.25.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, August 8th. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.08. On average, equities analysts anticipate that Disc Medicine, Inc. will post -4.19 EPS for the current year.

Analyst Upgrades and Downgrades

IRON has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Friday, September 20th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $70.00 price target (up previously from $50.00) on shares of Disc Medicine in a research note on Monday, June 17th. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Disc Medicine in a research report on Monday, September 16th. Wells Fargo & Company initiated coverage on shares of Disc Medicine in a research report on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 target price for the company. Finally, Wedbush reiterated an “outperform” rating and set a $57.00 price target on shares of Disc Medicine in a research report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and a consensus target price of $64.13.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC increased its holdings in shares of Disc Medicine by 14.2% during the fourth quarter. Perceptive Advisors LLC now owns 1,023,045 shares of the company’s stock valued at $59,091,000 after acquiring an additional 127,404 shares in the last quarter. Frazier Life Sciences Management L.P. increased its stake in Disc Medicine by 19.8% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 785,000 shares of the company’s stock valued at $45,342,000 after purchasing an additional 130,000 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in Disc Medicine in the first quarter worth about $7,429,000. Jennison Associates LLC lifted its stake in shares of Disc Medicine by 349.1% in the first quarter. Jennison Associates LLC now owns 193,240 shares of the company’s stock worth $12,031,000 after buying an additional 150,209 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Disc Medicine by 59.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock valued at $58,788,000 after buying an additional 353,382 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.